TNF and inflammatory bowel disease: In summary, despite the outlined evidence that pediatric patients with IBD are at increased risk for immunogenicity, and the knowledge that approved biologic treatments for children are limited to anti-TNF-α, clinicians face many challenges in implementing judicious, proactive therapeutic drug monitoring to detect immunogenicity in every-day IBD practice.